Zugo-cel (CTX112)
In Development
CRISPR Therapeutics
Overview
An allogeneic, gene-edited anti-CD19 CAR-T cell therapy (zugocaptagene geleucel) being developed for autoimmune diseases such as lupus as well as relapsed/refractory B-cell cancers, using CRISPR editing to make an off-the-shelf product.
Phase 1/2, with RMAT designation. Oncology data show a 90% overall response rate and 70% complete response; early autoimmune data show drug-free remissions in lupus. Additional readouts expected in H2 2026, supported by a clinical-supply deal with Eli Lilly.